%0 Journal Article %1 Schmitz.2010 %A Schmitz, Norbert %A Trümper, Lorenz %A Ziepert, Marita %A Nickelsen, Maike %A Ho, Anthony D. %A Metzner, Bernd %A Peter, Norma %A Loeffler, Markus %A Rosenwald, Andreas %A Pfreundschuh, Michael %D 2010 %J Blood %K Adolescent Adult Aged Antineoplastic_Combined_Chemotherapy_Protocols/administration_&_dosage/therapeutic_use Cohort_Studies Cyclophosphamide/administration_&_dosage/therapeutic_use Doxorubicin/administration_&_dosage/therapeutic_use Female Humans Killer_Cells,_Natural/pathology Lymphoma,_Extranodal_NK-T-Cell/diagnosis/drug_therapy/pathology Lymphoma,_Non-Hodgkin/diagnosis/drug_therapy/pathology Lymphoma,_T-Cell/diagnosis/drug_therapy/pathology Male Middle_Aged Prednisone/administration_&_dosage/therapeutic_use Prognosis Treatment_Outcome Vincristine/administration_&_dosage/therapeutic_use Young_Adult %N 18 %P 3418–3425 %T Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group %V 116 %X To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28). Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP). Three-year event-free survival (EFS) and overall survival were 75.8\% and 89.8\% (ALK-positive ALCL), 50.0\% and 67.5\% (AITL), 45.7\% and 62.1\% (ALK-negative ALCL), and 41.1\% and 53.9\% (PTCLU), respectively. The International Prognostic Index (IPI) was effective in defining risk groups with significantly different outcomes. For patients, ≤ 60 years with lactate dehydrogenase ≤ upper normal value (UNV), etoposide improved improved 3-year EFS: 75.4\% versus 51.0\%, P = .003. In patients > 60 years 6 courses of CHOP administered every 3 weeks remains the standard therapy. Patients with ALK-negative ALCL, PTCLU, or AITL presenting with IPI > 1 have a poor prognosis and should be considered candidates for novel treatment strategies.

@article{Schmitz.2010, abstract = {To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28). Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP). Three-year event-free survival (EFS) and overall survival were 75.8\% and 89.8\% (ALK-positive ALCL), 50.0\% and 67.5\% (AITL), 45.7\% and 62.1\% (ALK-negative ALCL), and 41.1\% and 53.9\% (PTCLU), respectively. The International Prognostic Index (IPI) was effective in defining risk groups with significantly different outcomes. For patients, ≤ 60 years with lactate dehydrogenase ≤ upper normal value (UNV), etoposide improved improved 3-year EFS: 75.4\% versus 51.0\%, P = .003. In patients > 60 years 6 courses of CHOP administered every 3 weeks remains the standard therapy. Patients with ALK-negative ALCL, PTCLU, or AITL presenting with IPI > 1 have a poor prognosis and should be considered candidates for novel treatment strategies.}, added-at = {2014-10-14T15:28:10.000+0200}, author = {Schmitz, Norbert and Trümper, Lorenz and Ziepert, Marita and Nickelsen, Maike and Ho, Anthony D. and Metzner, Bernd and Peter, Norma and Loeffler, Markus and Rosenwald, Andreas and Pfreundschuh, Michael}, biburl = {https://www.bibsonomy.org/bibtex/27101cc5ef1e62515371f3ed28836b275/drtester}, interhash = {3be5a6d346494a4884a7ff37436b648c}, intrahash = {7101cc5ef1e62515371f3ed28836b275}, journal = {Blood}, keywords = {Adolescent Adult Aged Antineoplastic_Combined_Chemotherapy_Protocols/administration_&_dosage/therapeutic_use Cohort_Studies Cyclophosphamide/administration_&_dosage/therapeutic_use Doxorubicin/administration_&_dosage/therapeutic_use Female Humans Killer_Cells,_Natural/pathology Lymphoma,_Extranodal_NK-T-Cell/diagnosis/drug_therapy/pathology Lymphoma,_Non-Hodgkin/diagnosis/drug_therapy/pathology Lymphoma,_T-Cell/diagnosis/drug_therapy/pathology Male Middle_Aged Prednisone/administration_&_dosage/therapeutic_use Prognosis Treatment_Outcome Vincristine/administration_&_dosage/therapeutic_use Young_Adult}, number = 18, pages = {3418–3425}, timestamp = {2014-10-14T15:28:10.000+0200}, title = {Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group}, volume = 116, year = 2010 }